Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti‑CD38monoclonal antibodies

Costa L, et al.
Annals of Hematology
January 2025
Authors and Affiliates
Luciano J. Costa1 · Francesca Gay2 · Ola Landgren3 · María‑Victoria Mateos4 · Philippe Moreau5 · Cyrille Touzeau5 · Franziska Ertel6 · Ian McFadden7 · Rani Najdi7 · Katja Weisel8 1 Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL 35294, USA 2 AOU Città Della Salute E Della Scienza Di Torino, University of Torino, Turin, Italy 3 Division of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA 4 University Hospital Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain 5 The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France 6 Amgen GmbH, Munich, Germany 7 Amgen Inc, Thousand Oaks, CA, USA 8 Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem O, et al.
Nature Communications
January 2025
Authors and Affiliates
Omar Nadeem1,2,8 , Michelle P. Aranha 1,2,3,8, Robert Redd 4, Michael Timonian 1,2,3, Sophie Magidson 1, Elizabeth D. Lightbody1,2,3, Jean-Baptiste Alberge 1,2,3, Luca Bertamini1,2,3, Ankit K. Dutta1,2,3, Habib El-Khoury1,2,3, Mark Bustoros 1,5, Jacob P. Laubach1, Giada Bianchi6, Elizabeth O’Donnell1, TingWu3, Junko Tsuji3, Kenneth C. Anderson 1, Gad Getz2,3,7, Lorenzo Trippa4, Paul G. Richardson1, Romanos Sklavenitis-Pistofidis1,2,3 & Irene M. Ghobrial 1,2,3 1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2Harvard Medical School, Boston,MA,USA. 3Broad Institute ofMIT andHarvard,Boston,MA,USA. 4Department of Biostatistics andComputational Biology,Dana-Farber Cancer Institute, Boston, MA, USA. 5Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY, USA. 6Amyloidosis Program, Division of Hematology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston,MA, USA. 7Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. 8These authors contributed equally: Omar Nadeem, Michelle P. Aranha.

A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease

Davids M, et al.
Journal of Clinical Oncology
December 2024
Authors and Affiliates
Matthew S. Davids, M.D., M.M.Sc.1, Christine E. Ryan, M.D.1, Benjamin L. Lampson, M.D., Ph.D.1, Yue Ren, M.S.2, Svitlana Tyekucheva, Ph.D.2, Stacey M. Fernandes, B.S.1, Jennifer L. Crombie, M.D.1, Austin I. Kim, M.D.1, Matthew Weinstock, M.D.3, Josie Montegaard, N.P.1, Heather A. Walker, M.P.H.1, Claire Greenman, B.A.,1 Victoria Patterson, R.N.1, Caron A. Jacobson, M.D., M.M.Sc.1, Ann S. LaCasce, M.D., M.M.Sc.1, Philippe Armand, M.D., Ph.D.1, David C. Fisher, M.D.1, Steve Lo, M.D.,4 Adam J. Olszewski, M.D.,5 Jon E. Arnason, M.D.3, Inhye E. Ahn, M.D.1, Jennifer R. Brown, M.D., Ph.D.1 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA 3Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA 4Stamford Hospital, Stamford, CT, USA 5Brown University Health, Providence, RI, USA

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Vogl D, et al.
Blood
December 2024
Authors and Affiliates
Dan T. Vogl,1 Shebli Atrash,2 Sarah A. Holstein,3 Omar Nadeem,4 Don Benson,5 Maria Chaudry,5 Noa Biran,6 Kaveri Suryanarayan,7 Cheryl Li,7 Yuyin Liu,7 Sabrina Collins,7 Xavier Parot,7 and Jonathan L. Kaufman8 Affiliations: 1 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2 Levine Cancer Institute, Charlotte, NC, USA; 3University of Nebraska Medical Center, Omaha, NE, USA; 4 Dana-Farber Cancer Institute, Boston, MA, USA; 5 Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; 6John Theurer Cancer Center, Hackensack, NJ, USA; 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA; 812 Winship Cancer 13 Institute of Emory University, Atlanta, GA, USA

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Bhutani M, et al.
Blood Advances
November 2024
Authors and Affiliates
Manisha Bhutani,1,* Myra Robinson,2 David Foureau,3 Shebli Atrash,1 Barry Paul,1 Fei Guo 3, Jason M Grayson 4, Anna Ivanina-Foureau, 3 Mauricio Pineda-Roman,1 Cindy Varga,1 Reed Friend,1 Christopher J. Ferreri,1 Xhevahire Begic,5 Sarah Norek,5 Tiffany Drennan,6 Michelle B Anderson,2 James T. Symanowski,2 Peter M. Voorhees,1,** and Saad Z. Usmani7,*** 1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA 2Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA 3Immune Monitoring Core Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC, USA 4Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston- Salem, NC, USA 5Atrium Health Wake Forest Baptist Comprehensive Cancer Center Data Coordinating Center, Levine Cancer Institute, Charlotte, NC 6Clinical Trials Unit, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA 7Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients

Chen L, et al.
Blood Advances
November 2024
Authors and Affiliates
Lucia Y Chen1, Santiago Thibaud2, Saoirse Bodnar2, Ajai Chari3, Joshua Richter2, Hearn Jay Cho2, Larysa J Sanchez2, Cesar Rodriguez2, Adriana C Rossi2, Shambavi Richard2, Samir Parekh2, Sundar Jagannath2* 1. Weatherall Institute of Molecular Medicine, Oxford University, UK 2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA 3. University of California, San Francisco, California, USA

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Roloff G, et al.
J Clin Oncol
October 2024
Authors and Affiliates
Gregory W. Roloff, MD1; Ibrahim Aldoss, MD2 ; Noam E. Kopmar, MD3 ; Chenyu Lin, MD4 ; Simone E. Dekker, MD, PhD5; Vishal K. Gupta, MD6 ; Timothy E. O’Connor, MD7; Nikeshan Jeyakumar, MD8; Ibrahim N. Muhsen, MD9 ; Yannis Valtis, MD10 ; Naveed Ahmed, DO10; Amy Zhang, MPH8; Katharine Miller, PhD, MPH8 ; Kaitlyn C. Dykes, MD11; Mohamed Ahmed, MD12; Evan C. Chen, MD13 ; Santiago Mercadal, MD14 ; Marc Schwartz, MD15; Sean I. Tracy, MD, PhD16 ; Bhagirathbhai Dholaria, MBBS17 ; Akash Mukherjee, MD18; Minoo Battiwalla, MD, MS19 ; Aaron C. Logan, MD, PhD20 ; Abdullah Ladha, MD21 ; Caitlin Guzowski, MBA22; Rasmus T. Hoeg, MD23; Talal Hilal, MBBCh24 ; Jozal Moore, MD25; Matthew P. Connor, MD26 ; LaQuisa C. Hill, MD27 ; Stephanie B. Tsai, MD7; Joshua P. Sasine, MD, PhD12 ; Melhem M. Solh, MD22 ; Vamsi K. Kota, MD28 ; Divya Koura, MD11; Muthu Veeraputhiran, MD18; Jessica T. Leonard, MD5; Noelle V. Frey, MD, MS26 ; Jae H. Park, MD10 ; Marlise R. Luskin, MD, MSCE13 ; Veronika Bachanova, MD, PhD16; Ahmed Galal, MD4; Vinod Pullarkat, MD2; Wendy Stock, MD1 ; Ryan D. Cassaday, MD3 ; Bijal D. Shah, MD, MS29; Rawan Faramand, MD29; and Lori Muffly, MD, MS8 ; on behalf of the ROCCA Consortium 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 2Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 3Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 4Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC 5Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 6Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA 7Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL 8Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA 9Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 10Memorial Sloan Kettering Cancer Center, New York, NY 11Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA 12Cedars-Sinai Medical Center, Los Angeles, CA 13Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 14Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 15University of Colorado Anschutz School of Medicine, Aurora, CO 16Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 17Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 18University of Arkansas Medical Center, Little Rock, AK 19Sarah Cannon Transplant and Cell Therapy Network, Nashville, TN 20Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA 21Department of Hematology, Norris Cancer Center, University of Southern California, Los Angeles, CA 22Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA 23Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA 24Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 25Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 26Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 27Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX 28Georgia Cancer Center, Augusta University, Augusta, GA 29Moffitt Cancer Center, Tampa, FL

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Dimopoulos M, et al.
Blood Advances
October 2024
Authors and Affiliates
Meletios A. Dimopoulos,1 Daniel Coriu,2,3 Sosana Delimpasi,4 Ivan ˇ Spiˇcka,5 Terry Upchurch,6 Belle Fang,6 Rakhshandra Talpur,6 Edward Faber,7 Meral Beksac,8 and Xavier Leleu9 1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania; 3Department of Haematology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; 4Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece; 5First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic; 6Amgen Inc, Thousand Oaks, CA; 7Oncology Hematology Care, Inc, Cincinnati, OH; 8Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey; and 9Department of Hematology and Cellular Therapy, CIC U1402 CHU de Poitiers, Poitiers, France

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity(MRD2STOP)

Derman B, et al.
Blood Cancer Journal
October 2024
Authors and Affiliates
Benjamin A. Derman1✉, Ajay Major 2, Jennifer Cooperrider1, Ken Jiang1, Aubrianna Ramsland1, Theodore Karrison3, Tadeusz Kubicki 1 and Andrzej J. Jakubowiak1 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. 2Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. 3Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Sidana S, et al.
Blood
October 2024
Authors and Affiliates
Surbhi Sidana1*, Krina K. Patel2*, Lauren C. Peres*3, Radhika Bansal4, Mehmet H. Kocoglu5, Leyla Shune6, Shebli Atrash7, Kinaya Smith8, Shonali Midha9, Christopher Ferreri,7, Binod Dhakal8, Danai Dima10, Patrick Costello9, Charlotte Wagner11, Ran Reshef12, Hitomi Hosoya1, Lekha Mikkilineni1, Djordje Atanackovic5, Saurabh Chhabra13, Ricardo Parrondo14, Omar Nadeem9, Hashim Mann,15 Nilesh Kalariya2, Vanna Hovanky1, Gabriel De Avila3, Ciara L Freeman3, Frederick L. Locke3, Melissa Alsina3, Sandy Wong16, Megan Herr17, Myo Htut18, Joseph McGuirk6, Douglas W. Sborov11, Jack Khouri10, Thomas Martin16, Murali Janakiram18*, Yi Lin4*, and Doris K. Hansen3* *S.S, K.K.P, L.C.P are co-first authors; M.J, Y.L, and D.K.H are co-senior authors. Affiliations: 1. Stanford University School of Medicine 2. The University of Texas MD Anderson Cancer Center, 3. Moffitt Cancer Center, 4. Mayo Clinic, Rochester, 5. University of Maryland School of Medicine, 6. University of Kansas Medical Center, 7. Levine Cancer Institute, 8. Medical College of Wisconsin, 9. Dana-Farber Cancer Institute, 10. Cleveland Clinic Taussig Cancer Center. 11. Huntsman Cancer Institute at the University of Utah, 12. Columbia University Irving Medical Center, 13. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, 14. Mayo Clinic, Jacksonville 15. Virginia Commonwealth University, 16. University of California San Francisco, 17. Rosewell Park Cancer Center, 18. City of Hope Comprehensive Cancer Center,